Notably, although such benefits were initially demonstrated in patients with type 2 diabetes, they have subsequently also been demonstrated in populations of patients without diabetes, i.e., in patients with heart failure [12] and chronic kidney disease [13] (for SGLT2i), or in patients with obesity (for GLP1-RA) [14, 15], thereby suggesting that their benefits may be, at least partially, independent of the specific pathophysiology of type 2 diabetes. This evidence concerns the gene GLP1R and chronic kidney disease.